ReviewAdvances in pharmacology (San Diego, Calif.)2012
Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.
Review in Advances in pharmacology (San Diego, Calif.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Disrupting Mechanisms that Regulate Genomic Repeat Elements to Combat Cancer and Drug Resistance.Frontiers in cell and developmental biology · 2022Pooled it
- Pre-existing cell states predict resistance to multiple treatments.Cell genomics · 2026Article
- Single-cell data analysis of lung cancer brain metastasis reveals SEC61G serves as a potential risk indicator.Discover oncology · 2026Article
- Lamin B receptor upregulation in metastatic melanoma causes nuclear envelope fragility in confined migration during cancer invasion.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Biopsy RNA-seq captures TROP-2-linked migration and clonal resistance to forecast aggressiveness in metastatic melanoma.Journal of experimental & clinical cancer research : CR · 2026Article
- The Suicide Gene System Cytosine Deaminase::Uracylphosphoribosyltransferase/5-fluorocytosine Displays a Strong Cytotoxic Effect on Human Melanoma Cells.Current pharmaceutical biotechnology · 2026Article
- The Role of Glucose-6-Phosphate Dehydrogenase in Skin Cancer Metabolism: A Paradigm Shift in Treatment Approaches.Cancers · 2024Review
- Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response.Pharmacology & therapeutics · 2023Review
- Drug screening at single-organoid resolution via bioprinting and interferometry.Nature communications · 2023Article
- Nanotheranostic Strategies for Cancer Immunotherapy.Small methods · 2022Review
- Tepotinib suppresses proliferation, invasion, migration, and promotes apoptosis of melanoma cells via inhibiting MET and PI3K/AKT signaling pathways.Oncology letters · 2022Article
- MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy.International journal of molecular sciences · 2021Article
- Using single-cell sequencing technology to detect circulating tumor cells in solid tumors.Molecular cancer · 2021Review
- Review
- The lingering mysteries of metastatic recurrence in breast cancer.British journal of cancer · 2021Review
- Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?Frontiers in oncology · 2021Article
- Decoding Immune Heterogeneity of Melanoma and identifying immune-prognostic hub genes.Journal of Cancer · 2021Article
- WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion.Nature communications · 2020Article
- The Potential of Tumor Debulking to Support Molecular Targeted Therapies.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Malignant melanoma is an aggressive form of skin cancer whose incidence continues to increase worldwide. Increased exposure to sun, ultraviolet radiation, and the use of tanning beds can increase the risk of melanoma. Early detection of melanomas is the key to successful treatment mainly through surgical excision of the primary tumor lesion. But in advanced stage melanomas, once the disease has spread beyond the primary site to distant organs, the tumors are difficult to treat and quickly develop resistance to most available forms of therapy. The advent of molecular and cellular techniques has led to a better characterization of tumor cells revealing the presence of heterogeneous melanoma subpopulations. The discovery of gene mutations and alterations of cell-signaling pathways in melanomas has led to the development of new targeted drugs that show dramatic response rates in patients. Single-agent therapies generally target one subpopulation of tumor cells while leaving others unharmed. The surviving subpopulations will have the ability to repopulate the original tumors that can continue to progress. Thus, a rational approach to target multiple subpopulations of tumor cells with a combination of drugs instead of single-agent therapy will be necessary for long-lasting inhibition of melanoma lesions. In this context, the recent development of immune checkpoint reagents provides an additional armor that can be used in combination with targeted drugs to expand the presence of melanoma reactive T cells in circulation to prevent tumor recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.